Institute of Medicine report concludes that the FDA is not doing adequate job of assessing drug benefits and risks

by | May 8, 2012 | antidepressants, clinical trials, drug marketing, FDA, media coverage, National Institutes of Health, patient care, pharmaceutical industry, Uncategorized

Two weeks ago, I headlined my blog with this question: Is the FDA violating its own mandate to approve safe drugs? Four days later, the national Institute of Medicine (IOM) released a 233-page report concluding that FDA’s current approach to drug oversight “is...

Is the FDA violating its own mandate to approve safe drugs?

by | Apr 27, 2012 | antidepressants, biotech industry, clinical trials, continuing medical education, drug marketing, FDA, health care costs, medical devices, patient care, pharmaceutical industry, scientific misconduct, suicide rates, Uncategorized

Is the Food and Drug Administration violating its own mandate to approve safe drugs? That was the question that Donald Light, co-author of The Risk for Prescription Drugs and a long-time medical sociologist, posed at a talk yesterday at Brandeis University. The...